

How the safety profile of POLA-R-CHP compares to that of R-CHOP

Roche: The overall safety profile of POLA-R-CHP is similar to that of R-CHOP and consistent with the known risk of the individual study drugs. Dr Franck Morschhauser gives us an overview of the safety data.

Dr Franck Morschhauser (MD, PhD, Professor of Hematology, University of Lille): Was the safety profile different for R-CHP-POLA compared to R-CHOP? There were no significant differences in terms of SAEs, Grade 3, 4, Grade 5, or AE leading to discontinuation of any study drug, in particular the microtubule inhibitors. The safety profile was almost the same.

Roche: What were the differences between the two treatment arms in terms of safety? Dr Franck Morschhauser elaborates.

Dr Franck Morschhauser: Another key finding of the study was that the safety profiles were pretty similar with R-CHP-POLA and R-CHOP. There were slightly more diarrhoea, slightly more febrile neutropenia, but really rates that were not different from what has been observed with R-CHOP in other series such as GOYA.

And as can be seen on this slide, in fact, the percentage of discontinuation for Polatuzumab was actually slightly lower, it's a numerical trend with polatuzumab compared to vincristine and same phenomenon for the dose reduction of any drug. The percentage were similar, but slightly lower in the test arm.

Reference:

1. Tilly H, et al. N Engl J Med. 2022;386:351-63.

1/1